Document is current
Any future updates will be listed below
-
Authors
Kimpel, Otilia
Schindler, Paul
Schmidt-Pennington, Laura https://orcid.org/0000-0001-9990-6387
Altieri, Barbara
Megerle, Felix
Haak, Harm
Pittaway, James
Dischinger, Ulrich
Quinkler, Marcus
Mai, Knut
Kroiss, Matthias
Polat, Bülent
Fassnacht, Martin https://orcid.org/0000-0001-6170-6398
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (314061271)
- License Information
-
More Information
Article History
Received: 9 October 2022
Revised: 15 November 2022
Accepted: 17 November 2022
First Online: 8 December 2022
Competing interests
: MK received travel cost reimbursement, speaker honoraria, and research support from Ipsen Pharma. MF has served in an advisory board of HRA Pharma on the management of adrenocortical carcinoma. Remunerations paid to his university hospital. OK received speaker honoraria from HRA Pharma. PS, LSP, BA, MQ, JP, HH, UD, KM, BP declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
: This cohort study was part of the ENSAT registry study () in five European reference centres for ACC (Würzburg, Germany; Berlin, Germany; Munich, Germany; London, UK; Eindhoven, Netherlands). It was approved by the ethics committees/institutional review boards at all participating institutions and all patients provided written informed consent.
